Contributing correspondent Kai Kupferschmidt talks with host Sarah Crespi about the success of a fast moving megatrial for coronavirus treatments. The United Kingdom’s Recovery (Randomized Evaluation of COVID-19 Therapy) trial has enrolled more than 12,000 hospitalized coronavirus patients since early March and has released important recommendations that were quickly taken up by doctors and scientists around the world.
Kupferschmidt discusses why such a large study is necessary and why other large drug trials like the World Health Organization’s Solidarity trial are lagging behind. Also this week, producer Meagan Cantwell talks with Saul Villeda, a professor in the Department of Anatomy at the University of California, San Francisco, about transferring the beneficial effects of exercise on the brain from an active mouse to a sedentary mouse by transferring their blood.

A selection of three essential articles read aloud from the latest issue of The Economist. This week,
Researchers have run numerous military-style simulations to predict the consequences of fictitious viral outbreaks. We discuss how these simulations work, what recommendations come out of them and if any of these warnings have been heeded.
Elderly people in nursing homes make up 45% of COVID-19 related deaths in the US. Nursing home alternatives have been on the rise for the last decade, but the pandemic has made alternatives more urgent.
We take a look back over the past six months of the pandemic, and discuss how far the world has come. It’s been a period of turmoil and science has faced an unprecedented challenge. What lessons can be learned from the epidemic so far to continue the fight in the months to come?

